Vaccine (Peptide vaccine) · Immune activation, directed at KRAS and NRAS · developed by Elicio Therapeutics
ELI-002 is a peptide-based cancer vaccine combining lipid-conjugated KRAS mutant peptides with a CpG-based adjuvant. It stimulates cytotoxic T-cell responses against KRAS and NRAS-expressing tumors. The vaccine is studied in pancreatic cancer, colorectal cancer, lung cancer, ovarian cancer, and cholangiocarcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05726864 | Phase 1/2 | Pancreatic Ductal Adenocarcinoma | Active not recruiting | ELTX |
| NCT04853017 | Phase 1 | Minimal Residual Disease | Completed | ELTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
KRAS G12AKRAS G12CKRAS G12SKRAS G12VKRAS G13DNRAS G12CNRAS G12SNRAS G12VBile Duct CancerCholangiocarcinomaColorectal CancerGallbladder CarcinomaKRAS G12DKRAS G12R
Updated Oct 3, 2026. Something wrong or missing? Report it on the ELTX page.
See ELTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ELTX catalysts and pipeline →